Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

References

• FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [webpage on the internet]LyonInternational Agency for Research on Cancer2013 Available from: http://globocan.iarc.fr/Default.aspxAccessed March 19, 2015
   Google Scholar
• FormanDBurleyVGastric cancer: global pattern of the disease and an overview of environmental risk factorsBest Pract Res Clin Gastroenterol20062063364916997150
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOTargeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspectsCrit Rev Oncol/Hematol20159311827
   PubMed Web of Science ®Google Scholar
• MihaljevicALFriessHSchuhmacherCClinical trials in gastric cancer and the futureJ Surg Oncol2013107328929710.1002/Jso.2312022514058
   PubMed Web of Science ®Google Scholar
• WashingtonK7th edition of the AJCC cancer staging manual: stomachAnn Surg Oncol201017123077307910.1245/s10434-010-1362-z20882416
   PubMed Web of Science ®Google Scholar
• KitagawaYTakeuchiHTakagiYSentinel node mapping for gastric cancer: a prospective multicenter trial in JapanJ Clin Oncol201331293704371010.1200/JCO.2013.50.378924019550
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN guidelines for gastric cancerFort Washington, PANational Comprehensive Cancer Network2015 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed March 19, 2015
   Google Scholar
• HopkinsSYangGYFDG PET imaging in the staging and management of gastric cancerJ Gastrointest Oncol201121394410.3978/j.issn.2078-6891.2010.00422811826
   PubMedGoogle Scholar
• CunninghamDAllumWHStenningSPPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med2006355112016822992
   PubMed Web of Science ®Google Scholar
• Van HagenPHulshofMCvan LanschotJJPreoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med20123662074208422646630
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol2006244991499717075117
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med2008358364618172173
   PubMed Web of Science ®Google Scholar
• SasakoMSakuramotoSKataiHFive-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancerJ Clin Oncol2011294387439322010012
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol2008921522118282805
   PubMed Web of Science ®Google Scholar
• CervantesARodaDTarazonaNRosellóSPérez-FidalgoJACurrent questions for the treatment of advanced gastric cancerCancer Treat Rev2013391606710.1016/j.ctrv.2012.09.00723102520
   PubMed Web of Science ®Google Scholar
• ObaKPaolettiXBangYJGASTRIC GroupRole of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysisEur J Cancer20134971565157710.1016/j.ejca.012.12.01623352439
   PubMed Web of Science ®Google Scholar
• WagnerADUnverzagtSGrotheWChemotherapy for advanced gastric cancerCochrane Database Syst Rev20103CD00406420238327
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet201037668769720728210
   PubMed Web of Science ®Google Scholar
• ESMO guidelines working groupEuropean Society of Medical Oncology (ESMO) guidelines for Gastric Cancer Available from: http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines/Gastrointestinal-Cancers/Gastric-Cancer2015Accessed March 2015
   Google Scholar
• HironakaSUedaSYasuiHRandomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trialJ Clin Oncol2013314438444424190112
   PubMed Web of Science ®Google Scholar
• KimHSKimHJKimSYSecond-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysisAnn Oncol2013242850285423942775
   PubMed Web of Science ®Google Scholar
• HanFHLiHMZhengDHHeYLZhanWHThe effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinomaEur J Surg Oncol2010361172117920888167
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJApatinib for chemotherapy refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel arm, phase II trialJ Clin Oncol2013313219322523918952
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJYongCJRamucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet2014383313924094768
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOTargeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedsideCrit Rev Oncol/Hematol20149414554
   PubMed Web of Science ®Google Scholar
• EllisLHicklinDVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer20088857959118596824
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF and the quest for tumour angiogenesis factorsNat Rev Cancer200221079580312360282
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• BurgosHAngiogenic and growth factors in human amnio-chorion and placentaEur J Clin Invest1983132892966193964
   PubMed Web of Science ®Google Scholar
• AusprunkDHFolkmanJMigration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesisMicrovasc Res1977145365895546
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun19891618518582735925
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOVascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerationsTumor Biol201435111061510625
   PubMed Web of Science ®Google Scholar
• GiatromanolakiAKoukourakisMISivridisEActivated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancerEur J Clin Invest2007371187888617883421
   PubMed Web of Science ®Google Scholar
• OlssonAKDimbergAKreugerJClaesson-WelshLVEGF receptor signalling – in control of vascular functionNat Rev Mol Cell Biol20067535937116633338
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med20083582039204918463380
   PubMed Web of Science ®Google Scholar
• KowanetzMFerraraNVascular endothelial growth factor signaling pathways: therapeutic perspectiveClin Cancer Res200612175018502216951216
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer2008857959118596824
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience2005307586215637262
   PubMed Web of Science ®Google Scholar
• SpratlinJLCohenRBEadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol20102878078720048182
   PubMed Web of Science ®Google Scholar
• LuDShenJVilMDTailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activityJ Biol Chem2003278434964350712917408
   PubMed Web of Science ®Google Scholar
• MiaoHQHuKJimenezXPotent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2Biochem Biophys Res Commun200634543844516682007
   PubMed Web of Science ®Google Scholar
• JungYDMansfieldPFAkagiMEffects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse modelEur J Cancer2002381133114012008203
   PubMed Web of Science ®Google Scholar
• ZhuZHattoriKZhangHInhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activityLeukemia20031760461112646950
   PubMed Web of Science ®Google Scholar
• ChioreanEGHurwitzHICohenRBPhase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsAnn Oncol20152661230123725787923
   PubMed Web of Science ®Google Scholar
• UedaSSatohTGotohMGaoLDoiTA phase Ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomasOncologist201520549349425888272
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyRamucirumab: Prescribing Information2014 Available form: http://www.accessdatafdagov/drugsatfda_docs/label/2014/125477lblpdf3192015
   Google Scholar
• YoonHHBendellJCBraitehFSRamucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trialJ Clin Oncol2014325s Suppl; abstr 4004
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKVan CutsemEVRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol2014151224123525240821
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysisCrit Rev Oncol/Hematol2014923194207
   PubMed Web of Science ®Google Scholar
• QiWXSunYJTangLNShenZYaoYRisk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysisCrit Rev Oncol/Hematol2014893394403
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysisFuture Oncol201410121981199225386814
   PubMed Web of Science ®Google Scholar
• SantoniMContiAMassariFTreatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trialsInt J Cancer2015136111024415642
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta-analysisExpert Rev Anticancer Ther201515112914125482593
   PubMed Web of Science ®Google Scholar
• Full Prescribing Information: Stivarga Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdfAccessed April 10, 2013
   Google Scholar
• Full Prescribing Information: Avastin Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s267lbl.pdfAccessed April 10, 2013
   Google Scholar
• Full Prescribing Information: Zaltrap Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdfAccessed April 10, 2013
   Google Scholar
• OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• ShenLLiJXuJBevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)Gastric Cancer201518116817624557418
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624335201520617114652
   PubMed Web of Science ®Google Scholar
• UronisHEBendellJCAltomareIA phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomasOncologist201318327127223485624
   PubMed Web of Science ®Google Scholar
• PasquierEHonoreSPourroyBAntiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cellsCancer Res20056562433244015781659
   PubMed Web of Science ®Google Scholar
• De GramontAVan CutsemESchmollHJBevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialLancet Oncol2012131225123323168362
   PubMed Web of Science ®Google Scholar
• MoehlerMMuellerAHartmannJTAn open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancerEur J Cancer2011471511152021561763
   PubMed Web of Science ®Google Scholar
• BangYJKangYKKangWKPhase II study of sunitinib as second-line treatment for advanced gastric cancerInvest New Drugs2011291449145820461441
   PubMed Web of Science ®Google Scholar
• SunWPowellMO’DwyerPJCatalanoPAnsariRHBensonAB3rdPhase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203J Clin Oncol2010282947295120458043
   PubMed Web of Science ®Google Scholar
• SatohTYamadaYMuroKPhase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancerCancer Chemother Pharmacol20126943944621853311
   PubMed Web of Science ®Google Scholar
• PottsSJHuffSELangeHTissue pattern recognition error rates and tumor heterogeneity in gastric cancerAppl Immunohistochem Mol Morphol2013211213010.1097/PAI.0b013e31825552a322820657
   PubMedGoogle Scholar
• DurãesCAlmeidaGMSerucaRBiomarkers for gastric cancer: prognostic, predictive or targets of therapy?Virchows Arch2014464336737810.1007/s00428-013-1533-y24487788
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOTargeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applicationsExpert Rev Anticancer Ther201515223524525353620
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOInsulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentialsMed Oncol201532143125487446
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOHedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentialsTumor Biol201536313671374
   PubMedGoogle Scholar